glp-1/gip receptor agonists Frontiers Understand GLP-1/GIP Dual Agonist Tirzepatide

1 This equates to about 29.1 million people who could be visiting community pharmacies for diabetes medications and supplies

This is a pivotal step that may define the fate of many claims

[DOI] [PubMed] [Google Scholar] 13.Takeda J, Seino Y, Tanaka K, et al

Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data